Introduction Telix Pharmaceuticals is a company that specializes in the development and commercialization of oncology treatments. They focus on prostate, renal, and glioblastoma cancer care. Their products include TX250, TX591, and TX101. The company was established in 2015 by Andreas Kluge and Christian P. Behrenbruch and is based in Melbourne, Australia. |
Top 5 Drug Type | Count |
---|---|
Radiolabeled antibody | 7 |
Therapeutic radiopharmaceuticals | 6 |
Diagnostic radiopharmaceuticals | 6 |
Monoclonal antibody | 2 |
Radionuclide Drug Conjugates (RDC) | 2 |
Target |
Mechanism PSMA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Dec 2020 |
Target |
Mechanism PDGFRα inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date19 Oct 2016 |
Target |
Mechanism CAIX inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date07 Mar 2024 |
Sponsor / Collaborator |
Start Date19 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Gallium GA-68 Gozetotide ( PSMA ) | Prostatic Cancer More | Approved |
Girentuximab-Zr-89 ( CAIX ) | Renal Cell Carcinoma More | NDA/BLA |
177Lu rosopatamab tetraxetan ( PSMA ) | Metastatic castration-resistant prostate cancer More | Phase 3 |
Iodofalan (131I) ( SLC7A5 ) | Glioblastoma Multiforme More | Phase 3 |
Floretyrosine F18 | Glioblastoma More | Phase 3 |